GLP-1 medications before anesthesia or a cosmetic procedure: build the handoff

A person taking a GLP-1 medicine needs procedure-specific instructions from the team responsible for anesthesia or sedation; there is no universal “hold for seven days” rule that fits every drug, formulation, dose phase, symptom pattern, and procedure. Current labeling warns of rare pulmonary aspiration during general anesthesia or deep sedation, while multi-society guidance supports individualized risk assessment rather than an automatic stop for everyone.¹²

The practical job is to connect three records before the procedure: the prescribing plan, the procedural plan, and the anesthesia or sedation plan. A clinic intake checkbox is not the handoff.

Start by naming the procedure and depth of sedation

“Cosmetic procedure” can mean a facial performed while fully awake, injectable treatment with no sedation, a laser session using topical anesthetic, an office procedure with oral medication, monitored anesthesia care, deep sedation, or general anesthesia. The aspiration language in current GLP-1 labeling specifically concerns general anesthesia or deep sedation.¹ That does not mean medication history is irrelevant to lighter procedures; it means the risk question and responsible team differ.

Ask the facility to write the planned anesthesia depth and identify who owns the final medication instructions. If the answer is “sedation as needed,” the plan is not yet specific enough.

Delayed gastric emptying is the connecting mechanism

GLP-1–based medicines can delay gastric emptying. Current Zepbound labeling reports rare postmarketing cases of pulmonary aspiration in people receiving GLP-1 receptor agonists during general anesthesia or deep sedation despite reported adherence to preoperative fasting instructions.¹ The label also says available data are insufficient to determine whether temporarily stopping the drug or changing fasting recommendations reduces that occurrence.

That sentence supports disclosure and individualized planning; it does not prescribe one hold period. Aspiration is a procedural event in which stomach contents enter the airway. Residual gastric contents, symptoms, airway strategy, anesthesia depth, procedure urgency, and other conditions or medicines can all matter.

The exact formulation belongs in the record. Weekly injections, daily oral products, daily injections, and compounded products have different dosing schedules and sometimes different concentrations. “I take a GLP-1” is incomplete.

Risk assessment uses more than the last-dose date

The 2024 multi-society guidance identifies circumstances that may raise concern for delayed gastric emptying, including being in dose escalation, taking a higher dose, having gastrointestinal symptoms, and having another condition that can delay emptying.² The guidance frames the decision as shared among the patient, prescribing team, proceduralist, and anesthesia professional.

Build a one-page handoff:

A date without symptoms can miss active risk. Symptoms without the formulation and dose history can miss why risk changed. Capture both.

Current guidance is risk-based—and not perfectly uniform

The multi-society guidance says continuation may be reasonable when the team does not identify elevated risk. When concern exists, options can include a preprocedure liquid diet, adjustment of the anesthesia plan, point-of-care gastric ultrasound when available and appropriate, or delay in selected circumstances.² It describes itself as guidance based on limited evidence, not a universal evidence-graded rule.

A separate 2025 SPAQI multidisciplinary consensus also emphasizes symptoms and individualized assessment, but offers its own fasting and perioperative recommendations.³ Differences across professional statements are a reason to obtain the actual facility’s current protocol, not to blend intervals from several internet graphics.

Facility policies may be more conservative because they incorporate staffing, equipment, procedure type, and local risk tolerance. A blanket policy is operationally clear, but the patient still needs coordination if withholding the medicine could affect glucose management, appetite, access, or the original condition being treated.

Do not improvise a medication pause from a social post

Stopping and restarting can have consequences. A person using a GLP-1 medicine for diabetes may need a glucose-management plan. A long gap may affect tolerance or require reassessment of titration under product-specific instructions. Insurance or pharmacy access may complicate replacement. A compounded vial can make the actual dose or beyond-use date harder to reconstruct.

The anesthesia team owns procedure-safety instructions; the prescribing team owns the treatment plan. Neither handoff is complete until conflicts are reconciled in writing. If the procedure office says “stop it” and the prescriber says “continue,” ask the two teams to resolve the instruction rather than choosing one privately.⁴

Avoid compensating for a late instruction by prolonged fasting. Excessively extending fasting without direction can introduce dehydration, low blood sugar, discomfort, or medication problems and still does not prove the stomach is empty.

Gastric ultrasound is a tool, not a universal clearance test

Multi-society guidance lists point-of-care gastric ultrasound as one possible assessment when concern exists and local expertise is available.² It can help estimate whether the stomach appears empty or contains fluid or solid material near the procedure time. Its usefulness depends on operator skill, equipment, patient factors, timing, interpretation, and how the result changes the anesthesia plan.

An ultrasound result is not a permanent clearance. It does not replace history, symptoms, fasting records, or airway planning, and not every facility offers it. Ask whether it is part of a defined protocol and who interprets it.

Procedure-day questions are operational

Confirm where the procedure occurs and whether the anesthesia professional meets the patient before the day of service. Identify a number for new gastrointestinal symptoms, a dose error, or a changed procedure time. Know which events cause postponement and whether rescheduling fees apply.

For an office-based cosmetic procedure, use the Florida office-surgery guide to separate clinician credentials, office registration, inspection, private accreditation, and anesthesia records. These layers do not answer the GLP-1 question, but they show who should own each part of the handoff.

Restart instructions deserve the same specificity as preprocedure instructions. They may depend on procedure type, oral intake, nausea or vomiting, glucose plan, usual dose day, time since last dose, and the label or prescriber’s protocol. “Resume when you feel normal” is not a complete instruction.

Close the loop before the procedure date

1. Name the exact medicine. Record ingredient, brand or compounder, formulation, dose, schedule, indication, last dose, and recent escalation.
2. Name the anesthesia depth. Replace “awake,” “twilight,” or “put under” with the planned level and responsible anesthesia professional.
3. Report symptoms and modifiers. Include current gastrointestinal symptoms, diabetes therapy, and other conditions or medicines that may affect emptying.
4. Resolve conflicting instructions. Have the prescriber, proceduralist, and anesthesia team agree on the written medication, fasting, liquid-diet, and arrival plan.
5. Plan a changed-risk day. Know whom to call if symptoms, dosing, procedure time, or anesthesia depth changes and what could postpone the case.
6. Write the restart and follow-up plan. Assign dose timing, glucose or symptom monitoring when relevant, and the contact for postprocedure intake problems.

The decisive question is: “Given my exact GLP-1 product, dose phase, symptoms, other risks, and planned depth of anesthesia or sedation, what written preprocedure and restart instructions have my prescriber and anesthesia team agreed on?”